Aclarion, Inc. (FRA:IT20)
Germany · Delayed Price · Currency is EUR | Market Cap | 4.97M +19.5% |
| Revenue (ttm) | 73.32K +33.1% |
| Net Income | -8.05M |
| EPS | -5.55 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 214 |
| Open | 1.470 |
| Previous Close | 1.460 |
| Day's Range | 1.470 - 1.470 |
| 52-Week Range | 1.380 - 7.920 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About Aclarion
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standa... [Read more]
Financial Performance
In 2025, Aclarion's revenue was $75,730, an increase of 65.62% compared to the previous year's $45,724. Losses were -$7.24 million, 2.66% more than in 2024.
Financial numbers in USD Financial StatementsNews
Aclarion reports Nociscan validated by strong agreement with discography
Aclarion (ACON) announced the publication of an independent, peer-reviewed study in the European Spine Journal. Conducted by the London Spine Clinic, the study evaluated Nociscan against low-pressure ...
Aclarion Transcript: LD Micro 20th Annual Main Event Conference
Nociscan targets a stated $7B beachhead with chemical disc diagnostics and cited trial results of 97% success when positive discs were treated. CLARITY and payer engagement are central to scaling; $14.2M in cash supports runway into Q3 2027.
Aclarion reports 85% Q3 scan volume growth, $14.2M in cash
Aclarion (ACON) announced the publication of a shareholder letter from CEO Brent Ness covering Q3. The company reported 85% year-over-year scan volume growth in Q3, contributing to 117% growth for…
Aclarion broadens CLARITY trial enrollment criteria
Aclarion (ACON) announced an update to the enrollment criteria and expected timing of the initial readout from its pivotal CLARITY clinical trial. Based on current enrollment levels and the required…
Aclarion Transcript: Lytham Partners Fall 2026 Investor Conference
NOCISCAN's AI-powered platform targets a $32 billion global market for chronic back pain, showing strong clinical evidence and rapid commercial adoption in the U.K. and U.S. Ongoing trials and a robust patent portfolio support growth, with a cash runway into 2027.
Aclarion announces NYU Langone Health as new clinical site for CLARITY trial
Aclarion (ACON) announced NYU Langone Health as a new clinical site in its CLARITY trial. The CLARITY study is designed to demonstrate Nociscan’s clinical and economic value in spine surgery.
Aclarion adds University of Arizona Phoenix as tenth CLARITY trial site
Aclarion (ACON) announced the University of Arizona College of Medicine in Phoenix as a new clinical site in its CLARITY trial. The CLARITY study is designed to demonstrate Nociscan’s clinical…
Aclarion receives notice of allowance for patent
Aclarion (ACON) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application titled “Multi-Voxel Prescription for Lumbar Disc Evaluation.” ...
Aclarion Quarterly report: Q2 2026
Aclarion has published its Q2 2026 quarterly earnings report on August 6, 2026.
Aclarion Transcript: Planet MicroCap Las Vegas 2026
A biomarker-driven technology for chronic low back pain shows potential to improve first-time surgical accuracy from 54% to 97%, with rapid adoption in the U.K. and strong financial growth. Interim results from a pivotal trial are expected in Q4, supported by leading clinicians and robust IP.
Aclarion partners with PRIA Healthcare to expand access to Nociscan
Aclarion (ACON) announced the launch of a Market Access Program in partnership with PRIA Healthcare. The initiative is designed to advance Nociscan, Aclarion’s proprietary artificial intelligence-driv...
Aclarion rejects Echo Lake acquisition proposal
Aclarion (ACON) issued the following statement in response to a recent communication issued by Echo Lake Capital and its principal, Ephraim Fields: “Aclarion’s Board of Directors carefully reviewed Ec...
Aclarion to ‘carefully review and evaluate’ Echo Lake’s proposal
Aclarion (ACON) issued the following statement in response to the press release issued by Echo Lake Capital and its offer to acquire the company for $4.00 per share in cash…
Echo Lake offers to acquire Aclarion for $4 per share in cash
Ephraim Fields of Echo Lake Capital sent a letter to the Board of Directors of Aclarion (ACON). The letter criticized the directors’ performance, compensation and qualifications and noted the tremendo...
Echo Lake Capital Offers To Acquire Aclarion Inc.
Offers $4.00 per share in cash plus CVR Stock currently trades below the value of its cash and other assets Believes company's public shell worth at least another $6 million if Board effected a revers...
Aclarion Quarterly report: Q1 2026
Aclarion has published its Q1 2026 quarterly earnings report on May 13, 2026.
Aclarion enters second commercial agreement with Weill Cornell Medicine
Aclarion (ACON) announced it has established a second commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/We...
Aclarion Proxy statement: Proxy filing
Aclarion filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Aclarion announces $2.5M share repurchase program
Aclarion (ACON) announced that its board of directors has authorized a share repurchase program of up to $2.5M of the company’s outstanding common stock. Aclarion expects to execute the repurchase…
Aclarion granted U.S. patent for AI-driven back pain assessment
Aclarion (ACON) announced the issuance of a U.S. patent covering its machine learning-based platform for analyzing magnetic resonance spectroscopy, or MRS, data. Aclarion’s cloud-based platform, Nocis...
Aclarion Receives Pinnacle Award for AI Innovation
Recognition Follows 2025 HLTH Digital Health Award for Nociscan Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market BROOMFIELD, Colo., April 14, 2026 (GLOBE NEWSWIRE) -- Aclarion,...
Aclarion announces commercial agreement with Weill Cornell Medicine
Aclarion (ACON) announced it has established a commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cor...
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practice Nearly 100 Nociscans performed at The Londo...
Aclarion Proxy statement: Proxy filing
Aclarion filed a proxy statement on April 3, 2026, providing details for shareholder voting and corporate governance matters.
Echo Lake calls on Aclarion director David Neal to resign
Ephraim Fields of Echo Lake Capital sent a letter to David Neal, a member of the Board of Directors of Aclarion (ACON). The letter read, in part, “We believe we…